ATE281843T1 - Immunotherapie chronischer hepatitis b virusinfektion mittels dna-immunisierung - Google Patents

Immunotherapie chronischer hepatitis b virusinfektion mittels dna-immunisierung

Info

Publication number
ATE281843T1
ATE281843T1 AT98934440T AT98934440T ATE281843T1 AT E281843 T1 ATE281843 T1 AT E281843T1 AT 98934440 T AT98934440 T AT 98934440T AT 98934440 T AT98934440 T AT 98934440T AT E281843 T1 ATE281843 T1 AT E281843T1
Authority
AT
Austria
Prior art keywords
immunotherapy
chronic hepatitis
virus infection
dna immunization
hepatitis
Prior art date
Application number
AT98934440T
Other languages
English (en)
Inventor
Alfred M Prince
Betsy Brotman
Original Assignee
New York Blood Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc filed Critical New York Blood Ct Inc
Application granted granted Critical
Publication of ATE281843T1 publication Critical patent/ATE281843T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98934440T 1997-07-24 1998-07-10 Immunotherapie chronischer hepatitis b virusinfektion mittels dna-immunisierung ATE281843T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/899,553 US6020319A (en) 1997-07-24 1997-07-24 Nucleic acid based immunotherapy of chronic hepatitis B infection
PCT/US1998/014404 WO1999004812A1 (en) 1997-07-24 1998-07-10 Nucleic acid based immunotherapy of chronic hepatitis b infection

Publications (1)

Publication Number Publication Date
ATE281843T1 true ATE281843T1 (de) 2004-11-15

Family

ID=25411202

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934440T ATE281843T1 (de) 1997-07-24 1998-07-10 Immunotherapie chronischer hepatitis b virusinfektion mittels dna-immunisierung

Country Status (7)

Country Link
US (1) US6020319A (de)
EP (1) EP0998301B1 (de)
AT (1) ATE281843T1 (de)
AU (1) AU8395698A (de)
DE (1) DE69827495T2 (de)
ES (1) ES2231997T3 (de)
WO (1) WO1999004812A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133244A (en) 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
US7732423B2 (en) 1994-04-27 2010-06-08 Institut Pasteur Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis
US20060248617A1 (en) 2002-08-30 2006-11-02 Japan Science And Technology Corporation Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same
EP2320941A2 (de) * 2008-07-03 2011-05-18 Duke University Zusammensetzung und verfahren zur auslösung einer immunantwort

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit

Also Published As

Publication number Publication date
ES2231997T3 (es) 2005-05-16
WO1999004812A1 (en) 1999-02-04
AU8395698A (en) 1999-02-16
EP0998301A1 (de) 2000-05-10
DE69827495T2 (de) 2005-10-20
US6020319A (en) 2000-02-01
EP0998301B1 (de) 2004-11-10
DE69827495D1 (de) 2004-12-16

Similar Documents

Publication Publication Date Title
LU91498I2 (fr) Etanercept et ses dérivés pharmaceutiquement acceptables.
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
SI1270595T1 (sl) Protitelo proti CCR4 in njegov fragment
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
UA42668C2 (uk) Поліпептид, що має антигенні властивості вірусу гепатиту с (hcv) (варіанти), діагностичний реагент для виявлення антитіл до вірусу гепатиту с (варіанти), набір для виявлення антитіл до вірусу гепатиту с (варіанти), спосіб виявлення антитіл до вірусу гепатиту с (варіанти)
DK84194A (da) Rekombinant hepatitis B-virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenetiske polypeptider, DNA-sekvenser kodende herfor, fremgangsmåder til påvisning af hepatitis B-virus antistoffer i blodserum, fremgangsmåder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider, midler til påvisn
DK0663010T3 (da) Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
DE68924162D1 (de) Stressproteine und verwendungen dafür.
PT1415002E (pt) Tecnologia focada em anticorpos
ATE473750T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
MXPA05008526A (es) Metodos y composicion inmunogenica.
PT1347055E (pt) Compostos para imunoterapia e diagnóstico da tuberculose
IT1279684B1 (it) Siringa per iniezioni ipodermiche.
ID30223A (id) Penggunaan antibodi untuk vaksinasi melawan kanker
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
DE69827495D1 (de) Immunotherapie chronischer Hepatitis B Virusinfektion mittels DNA-Immunisierung
DK1272652T3 (da) Herpesvirus til immunmodulation
AR002006A1 (es) Un proceso para la purificacion de un antigeno de superficie de hepatitis b viral que comprende un peptido pres2
HU9200583D0 (en) Method for producing el peptides of rubeola
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
DE69106141D1 (de) Non-a non-b sequenzen.
DK0687181T3 (da) Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling
ATE374622T1 (de) Genetische impstoffe mit adjuvans
ATE274354T1 (de) Impfungsmethode zur effizienten induktion der t- lymphozyten zytotoxischantwort

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties